Takeda Pharmaceutical Company Limited (TAK) said Tuesday that the U.S. Food and Drug Administration has accepted its new drug application for oveporexton and granted Priority Review for the treatment of narcolepsy type 1.
The agency set a Prescription Drug User Fee Act goal date in the third quarter of this calendar year.
Narcolepsy type 1 is a chronic, rare neurological disorder marked by excessive daytime sleepiness and cataplexy, or sudden loss of muscle tone.
The application is supported by positive data from the Phase 3 FirstLight and RadiantLight studies.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.